Postoperative nausea and vomiting (PONV) is one of the most common and distressing complications after anaesthesia and surgery. PONV may result in wound dehiscence, bleeding, dehydration, electrolyte imbalance, pulmonary aspiration of gastric contents, and delayed hospital discharge. 1 Despite advances in the prevention of PONV and development of new drugs, the overall incidence of PONV has been reported to be between 20% and 30%, and can increase up to 80% in high-risk patients. 2 For the prevention of PONV, several anti-emetics of different pharmacological classes are available. Currently, selective 5-hydroxytryptamine type 3 (5-HT 3 ) receptor antagonists are frequently used for the prevention of PONV because of their efficacy and fewer side-effects compared with other anti-emetics. 3 4 Palonosetron, the latest 5-HT 3 receptor antagonist, exhibits significantly different characteristics from older 5-HT 3 receptor antagonists because of its unique chemical structure. Palonosetron has a greater receptor binding affinity and a much longer half-life, conferring a prolonged duration of action, exceeding 40 h, compared with other 5-HT 3 receptor antagonists. 5 6 In addition, palonosetron exhibits allosteric interactions and triggers receptor internalization resulting in a long-lived inhibition of receptor function.
receptor antagonists (ondansetron, dolasetron, granisetron) throughout the 5 day post-chemotherapy period. 8 -10 For the prevention of PONV, two identically designed multicentre, double-blind, placebo-controlled phase III efficacy trials were published. 11 12 One study showed that palonosetron effectively prevented PONV during the 0-72 h postoperative period. 11 However, another study showed that palonosetron effectively prevented PONV during the 0-24 h period after operation, but not during the 24-72 h postoperative period.
12
As a result, more clinical evidence is needed before palonosetron can be routinely used in the prevention of PONV. This randomized, double-blind, placebo-controlled study was designed to further evaluate the efficacy of palonosetron for preventing PONV during the first 72 h after operation.
Methods
The study was approved by the IRB of Soonchunhyang University Hospital (Ref: 2010-106) before study commencement and registered with CRiS (Ref: KCT0000537). After receiving written informed consent, 204 healthy inpatients with an ASA physical status of I -II, aged 20 -70 yr, who were undergoing elective surgery, were enrolled in this randomized, double-blinded, placebo-controlled study. The patient underwent laparoscopic cholecystectomy or herniorrhaphy, minor orthopaedic surgery, plastic surgery, mastoidectomy and/or tympanoplasty, thyroidectomy, or tonsillectomy. Exclusion criteria included pregnancy, body weight more than 30% above the ideal body weight, vomiting or retching within 24 h before the operation, administration of anti-emetics or steroids or psychoactive medications within 24 h before the operation, or patients who electively requested an i.v. patient-controlled analgesia (i.v. PCA) using fentanyl for postoperative pain control or received an i.v. PCA using fentanyl after operation.
Patients were randomly allocated to one of the two groups: palonosetron group (palonosetron 0.075 mg i.v.) or placebo group (normal saline i.v.). Randomization was performed before surgery using a computer-generated randomized number table. The envelopes were opened before induction of anaesthesia by a trained nurse not involved in the study. The nurse then prepared the appropriate study medication as an injectable solution (1.5 ml) placed in identical syringes, for i.v. administration after the induction of anaesthesia. All patients and investigators collecting the postoperative data were blinded to the randomization. A standardized anaesthesia regimen was followed. All patients received midazolam 3-5 mg i.m. for premedication 30 min before surgery. General anaesthesia was induced with propofol 2 mg kg 21 and fentanyl 2 mg kg 21 . Rocuronium 0.6 mg kg 21 was administered to facilitate tracheal intubation. Anaesthesia was maintained with sevoflurane or desflurane combined with nitrous oxide (50%). At the end of surgery, residual neuromuscular block was reversed with pyridostigmine and glycopyrrolate in all patients. Ketorolac (0.5 -1.0 mg kg 21 ) was administered for postoperative pain control. After surgery, patients were observed in the post-anaesthetic care unit for 1 h before ward transfer. The incidence of nausea and vomiting, severity of nausea, and use of rescue anti-emetics were evaluated at 1, 6, 24, 48, and 72 h after operation. An episode of vomiting was defined as either vomiting (expulsion of stomach contents) or retching (an involuntary attempt to vomit but not productive of stomach contents). The severity of nausea was assessed using a four-point verbal rating scale (none, mild, moderate, severe). Metoclopramide 10 mg was administered i.v. as rescue medication for PONV upon patient's request or complaint of nausea (≥ moderate nausea) or vomiting. For postoperative pain control, non-steroidal anti-inflammatory drugs (ketorolac, etc.) were given. Adverse events were evaluated and recorded by the investigator during the entire observation period. Patients were asked to rate their overall satisfaction with the anaesthetic experience on a three-point scale (satisfied, neutral, and dissatisfied) at 72 h after operation.
The primary outcome measured in this study was the incidence of PONV 0-24 h after operation, and the secondary outcome measured included the incidence of PONV 24-72 h after operation, the severity of nausea, use of rescue medication, and patient satisfaction.
The sample size was predetermined using power analysis based on the following assumptions: (i) the incidence of PONV would be 60% in the placebo group 13 ; and (ii) a 34% reduction in the incidence of PONV 11 (from 60% to 40%) by palo- 
Results
Among the 204 patients enrolled in this study, 15 patients were withdrawn from the study due to receiving i.v. PCA using fentanyl for pain control after being transferred to the ward. Therefore, only data obtained from the remaining 189 patients were analysed, 94 patients in the palonosetron group and 95 in the placebo group (Fig. 1 ). There were no significant differences between the groups with respect to patient characteristics, Apfel's risk score, duration of surgery, duration of anaesthesia, and type of surgery ( Table 1) .
The incidence of PONV was significantly lower in the palonosetron group than in the placebo group during the 0-24 h (33% vs 47%) and the 0-72 h postoperative period (33% vs 52%) (P,0.05), but not during the 24 -72 h postoperative period (6% vs 11%) ( Table 2 ).
The incidence of nausea was significantly lower in the palonosetron group than in the placebo group during the 0 -24 h (32% vs 47%) and 0 -72 h postoperative period (32% vs 52%) (P,0.05), but not during the 24 -72 h postoperative period (6% vs 11%) ( Table 2 ).
The incidence of vomiting was not significantly different between the groups throughout the entire observation periods ( Table 2) .
The severity of nausea during the 0-24 h postoperative period was less in the palonosetron group compared with the placebo group, but the difference was not statistically significant (P¼0.08) (Fig. 2) .
There was no significant difference in rescue anti-emetics used between the groups (Table 2 ). There was no significant difference with regard to patient satisfaction between the groups (Table 3 ). The more frequently reported adverse events were dizziness and headache, which were similar between the groups (Table 3) .
Discussion
This study demonstrated that palonosetron 0.075 mg i.v. effectively reduced PONV during the 0-24 and 0-72 h period after surgery under general anaesthesia, although there was no significant difference in PONV incidence during the 24-72 h postoperative period between the groups. In addition, palonosetron significantly reduced the incidence of nausea, but not of vomiting.
Although the precise aetiology of PONV is unknown, various risk factors have been identified for PONV which include female gender, non-smoker status, history of PONVor motion sickness, use of perioperative opioids, use of volatile anaesthetics, duration of surgery, duration of anaesthesia, and type of surgery. 2 14 In this study, these risk factors were similar in the two groups. Therefore, the difference in PONV incidence between the groups can be attributed to the study drug. Palonosetron 0.075 mg dose was chosen in this study based on the results of previous studies showing that palonosetron 0.075 mg was effective in reducing PONV compared with placebo. 11 12 In addition, palonosetron 0.075 mg has been (71%), vomiting (60%)]. This corresponds to a relative risk reduction of 31% for nausea, and a relative risk reduction of vomiting by 34% for patients treated with palonosetron 0.075 mg. In a study by Candiotti and colleagues 12 involving elective outpatient laparoscopic abdominal and gynaecological surgery, a single 0.075 mg i.v. dose of palonosetron significantly increased the complete response rate (no emetic episodes and no rescue medication) compared with placebo during the 0-24 h postoperative period, but not during the 24-72 h postoperative interval. During the 0-24 h postoperative interval, palonosetron 0.075 mg significantly reduced the incidence and severity of nausea, but did not significantly reduce vomiting incidence compared with placebo (33% vs 44%). The study demonstrated that palonosetron has more prominent antinausea effect than anti-vomiting effect.
In the current study, palonosetron 0.075 mg significantly reduced the incidence of PONV during the 0-24 h Fig 2 The distribution (%) of nausea severity by a four-point verbal rating scale (none, mild, moderate, severe). The severity of nausea in the palonosetron group was less than the placebo group during 0-24 h, but was not statistically significant (P¼0.08). There were also no significant differences between the groups during 24-48 h (P¼0.29) and 48-72 h (P¼0.12). Table 3 Incidence of adverse events and patient satisfaction. Data are number of patients (%). There were no significant differences between the groups postoperative period, but not during the 24 -72 h postoperative period, even though palonosetron significantly reduced the overall incidence of PONV during the 0-72 h postoperative period. Although postoperative discharge nausea and vomiting (PDNV) was somewhat different from PONV, the overall incidence of PDNV was reported at 37%, even though the majority of the patients received ondansetron or dexamethasone. 15 Kovac and colleagues 11 also reported that 48% of inpatients who did not receive anti-emetics experienced emesis or used rescue anti-emetics during the 24-72 h postoperative period. We believe that many of these patients may have experienced PONV beyond the 24 h postoperative period. In this study, the incidence was highest during the first 6 h postoperative period, and then decreased with time. Only 11% of patients in the placebo group experienced PONV during the 24-72 h postoperative interval. One possible reason for the low incidence of late PONV in this study may be due to non-use of postoperative opioids since PONV is strongly influenced by postoperative opioids use in a dose-related manner. 16 Owing to the low incidence (11%) of PONV in the placebo group, it was difficult to demonstrate palonosetron's effect on PONV during the 24-72 h period in this study.
During the 0 -24 h interval, our study showed that significantly fewer patients treated with palonosetron 0.075 mg experienced nausea compared with patients who received placebo (32% vs 47%). This corresponds to a relative risk reduction for nausea of 33% for patients treated with palonosetron. This is consistent with the 31% relative risk reduction of nausea as reported by Kovac and colleagues 11 in a previous study.
During the 0-24 h interval, palonosetron 0.075 mg significantly reduced the incidence of vomiting from 60% in the placebo group to 40% in the study of Kovac and colleagues. 11 This was, however, not reproduced in another report (from 44% to 33%). 12 In contrast to these previous reports, the incidence of vomiting in the placebo group was only 14% during the 0-24 h postoperative interval in this study. The low incidence of postoperative vomiting was also due to the non-use of postoperative opioids, because postoperative opioid use was a strong risk factor for postoperative vomiting. 16 17 Accordingly, this study could not demonstrate the anti-vomiting effect of palonosetron due to the overall low rate of vomiting in the placebo group (14%) even during the 0-24 h postoperative interval. The frequently reported adverse events for 5-HT 3 receptor antagonist are headache and dizziness. 18 In this study, the incidence of headache and dizziness were similar between the two groups. A possible limitation of this study was the low incidence of late PONV during the 24-72 h postoperative interval even in the placebo group. Perhaps too few patients were enrolled in this study to accurately evaluate palonosetron's effects on late PONV. A larger number of patients, 1000 patients, would be required to demonstrate palonosetron's effect on late PONV during the 24-72 h postoperative interval. Further studies are needed to investigate palonosetron's effects on late PONV in patients who are at high risk for PONV.
In conclusion, palonosetron 0.075 mg i.v. effectively reduced the incidence of PONV during the first 72 h after operation, mainly during the 0-24 h postoperative interval, in patients undergoing elective surgery with general anaesthesia. Additionally, during the 0-24 h postoperative interval, palonosetron effectively reduced the incidence of nausea with a 33% relative risk reduction.
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